Sean Johnson

9PUBLICATIONS
47CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMedical virologyTransplantation immunologyCounselling, wellbeing and community services
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 01, 2026
CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

|Apr 29, 2026
Random Survival Forest Versus Elastic-Net Regularized Cox Regression for Survival Prediction in Acute Myeloid Leukemia at Distinct Treatment Time Points: Model Performance Comparison Study.

|Aug 06, 2025
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Jad Othman, Nicola Potter, Sylvie D Freeman

|May 01, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Jad Othman, Nicola Potter, Adam Ivey

|Feb 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

Jad Othman, Nicola Potter, Adam Ivey

|Feb 08, 2024
Digital adaptation of the Standing up for Myself intervention in young people and adults with intellectual disabilities: the STORM feasibility study.

Katrina Scior, Lisa Richardson, Elizabeth Randell

Pageof 2

Frequent Collaborators

4 joint publications

Jad Othman

3 joint publications

Joanna Canham

3 joint publications

Sylvie D Freeman

3 joint publications

Nicola Potter